Regulation 3 Amendment of the Marketing Authorisations Regulations
The Marketing Authorisations Regulations are amended as follows.
In regulation 5 (consideration, and grant or refusal, of an application for, or for renewal or variation of, a United Kingdom marketing authorization), omit paragraph (2).
After regulation 5 (consideration, and grant or refusal, of an application for, or for renewal or variation of, a United Kingdom marketing authorization) insert the following regulation—
“ Classification of medicinal products
5A(1)Each marketing authorization granted by the licensing authority on or after 1st April 2002 shall be granted subject to a condition that the medicinal product to which the authorization relates is to be available—
(a)only on prescription;
(b)only from a pharmacy; or
(c)on general sale.
(2)Where prior to 1st April 2002 a medicinal product is subject to a marketing authorization and that authorization contains a statement that it is to be available on one or more of the following bases—
(a)only on prescription;
(b)only from a pharmacy; or
(c)on general sale,
it is a condition of the marketing authorization from 1st April 2002 that the product is to be available only on that basis or, as the case may be, those bases.”.
In regulation 6 (revocation, suspension or variation of a United Kingdom marketing authorization or the suspension of the use or marketing of medicinal products), omit paragraph (8).
Regulation 8 (control of sale or supply of relevant medicinal products) is hereby revoked.
In paragraph 6(2) of Schedule 5 (labels), for head (a) substitute—
“(a)if the product would be subject to restrictions imposed under section 58 of the Act if it contained a higher proportion or level of any substance, except where the product is for external use only or contains any of the substances described in head (c) of this sub-paragraph, the words “Warning. Do not exceed the stated dose”;”.